Bio-Rad Laboratories, Inc. (BIO)

NYSE: BIO · Real-Time Price · USD
276.91
-9.04 (-3.16%)
At close: Sep 10, 2025, 4:00 PM
276.91
0.00 (0.00%)
After-hours: Sep 10, 2025, 4:10 PM EDT
-3.16%
Market Cap7.51B
Revenue (ttm)2.55B
Net Income (ttm)319.20M
Shares Out 27.06M
EPS (ttm)11.49
PE Ratio24.61
Forward PE28.08
Dividendn/a
Ex-Dividend Daten/a
Volume230,121
Open284.88
Previous Close285.95
Day's Range276.52 - 287.94
52-Week Range211.43 - 387.99
Beta0.96
AnalystsStrong Buy
Price Target333.50 (+20.13%)
Earnings DateOct 29, 2025

About BIO

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science e... [Read more]

Sector Healthcare
Founded 1952
Employees 7,700
Stock Exchange NYSE
Ticker Symbol BIO
Full Company Profile

Financial Performance

In 2024, Bio-Rad Laboratories's revenue was $2.57 billion, a decrease of -3.92% compared to the previous year's $2.67 billion. Losses were -$1.84 billion, 189.4% more than in 2023.

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for BIO stock is "Strong Buy." The 12-month stock price target is $333.5, which is an increase of 20.13% from the latest price.

Price Target
$333.5
(20.13% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Biorad Medisys announces its entry into the US market with the launch of its new subsidiary Medtimo Inc.

PUNE, India, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Biorad Medisys, an Indian medical device manufacturer with a global footprint, has announced its entry into the US market with the launch of its subsidi...

5 days ago - GlobeNewsWire

Bio-Rad Laboratories, Inc. (BIO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Bio-Rad Laboratories, Inc. (NYSE:BIO) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 12:45 PM EDT Company Participants Roop Lakkaraju - Executive VP & CFO Norman Schwartz - Chai...

5 days ago - Seeking Alpha

Bio-Rad's Management to Participate in Upcoming Investor Conferences

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that members of the com...

16 days ago - Business Wire

Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause

The U.S. Government plans to cut the annual budget allocated to the NIH by 40% in 2026. This decision could have an adverse effect on the operations of Bio-Rad. Bio-Rad projects 0.5% revenue growth fo...

4 weeks ago - Seeking Alpha

Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings

Bio-Rad Laboratories, Inc. BIO reported better-than-expected second-quarter financial results on Thursday.

5 weeks ago - Benzinga

Bio-Rad to Host Droplet Digital PCR Webinar on Tuesday, August 26, 2025

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announced today that the company's mana...

5 weeks ago - Business Wire

Bio-Rad Laboratories, Inc. (BIO) Q2 2025 Earnings Call Transcript

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q2 2025 Earnings Conference Call July 31, 2025 5:00 PM ET Company Participants Jonathan P. DiVincenzo - President & COO Norman D.

5 weeks ago - Seeking Alpha

Bio-Rad Reports Second-Quarter 2025 Financial Results

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t...

5 weeks ago - Business Wire

Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the appointment of Raja...

6 weeks ago - Business Wire

Bio-Rad to Report Second Quarter 2025 Financial Results on Thursday, July 31, 2025

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for t...

7 weeks ago - Business Wire

Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of four new ...

2 months ago - Business Wire

Bio-Rad's Management to Host Investor Meetings During Jefferies Global Healthcare Conference

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chie...

3 months ago - Business Wire

Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Executiv...

4 months ago - Business Wire

Bio-Rad Laboratories, Inc. (BIO) Q1 2025 Earnings Call Transcript

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q1 2025 Earnings Conference Call May 1, 2025 5:30 PM ET Company Participants Edward Chung - Head of Investor Relations Jon DiVincenzo - President and Chief Opera...

4 months ago - Seeking Alpha

Bio-Rad Reports First-Quarter 2025 Financial Results

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t...

4 months ago - Business Wire

Bio-Rad Laboratories, Inc. (BIO) Q4 2024 Earnings Call Transcript

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Edward Chung - Vice President of Investor Relations Jon DiVincenzo - President...

7 months ago - Seeking Alpha

Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t...

7 months ago - Business Wire

Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company has en...

7 months ago - Business Wire

Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for t...

8 months ago - Business Wire

Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests

ST. LOUIS & HERCULES, Calif.--(BUSINESS WIRE)--Geneoscopy raises $105 million in Series C funding round, led by Bio-Rad Laboratories.

Other symbols: LH
8 months ago - Business Wire

Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chie...

8 months ago - Business Wire

Bio-Rad's Management to Host Investor Meetings at Citi's 2024 Global Healthcare Conference

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chie...

10 months ago - Business Wire

Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chie...

11 months ago - Business Wire

Bio-Rad Laboratories, Inc. (BIO) Q3 2024 Earnings Call Transcript

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q3 2024 Earnings Conference Call October 30, 2024 5:00 PM ET Company Participants Edward Chung - Vice President of Investor Relations Norman Schwartz - Chairman ...

11 months ago - Seeking Alpha

Bio-Rad Laboratories beats quarterly profit estimates on strong sales in diagnostics unit

Diagnostics firm Bio-Rad Laboratories posted third-quarter profit above Wall Street estimates on Wednesday, helped by a recovery in demand for analytical tools from its biotech clients and steady clin...

11 months ago - Reuters